| PRD_000316 | Name: | METHOXYSUCCINYL-ALA-ALA-PRO-VALINE BORONIC ACID | Formula: | C20 H35 B N4 O8 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_001091 | Name: | monomeric peptide inhibitor | Formula: | C72 H103 N19 O16 S2 | Definition date: | 2012-12-12 | Last modified: | 2013-06-03 |
|
| PRD_001092 | Name: | D-phenylalanyl-L-prolyl-N~5~-[amino(iminio)methyl]-D-ornithyl-L-cysteinamide | Formula: | C23 H37 N8 O4 S | Definition date: | 2012-12-12 | Last modified: | 2013-06-03 |
|
| PRD_000317 | Name: | N-(4-methoxy-4-oxobutanoyl)-L-alanyl-L-alanyl-N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-L-prolinamide | Formula: | C21 H37 B N4 O8 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000318 | Name: | N-(4-methoxy-4-oxobutanoyl)-L-alanyl-L-alanyl-N-[(1R)-1-(dihydroxyboranyl)pentyl]-L-prolinamide | Formula: | C21 H37 B N4 O8 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_001093 | Name: | D-phenylalanyl-L-prolyl-N~5~-[amino(iminio)methyl]-D-ornithyl-L-isoleucinamide | Formula: | C26 H43 N8 O4 | Definition date: | 2012-12-12 | Last modified: | 2013-06-03 |
|
| PRD_000319 | Name: | methyl N-{(2S,4S,5S)-5-[(L-alanyl-L-alanyl)amino]-2-benzyl-4-hydroxy-6-phenylhexanoyl}-L-valyl-L-valinate | Formula: | C36 H53 N5 O7 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000320 | Name: | methyl N-{(4S,5S)-5-[(L-alanyl-L-alanyl)amino]-4-hydroxy-6-phenylhexanoyl}-L-valyl-L-valinate | Formula: | C29 H47 N5 O7 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_001095 | Name: | N~2~-[(2S)-2-{[(benzyloxy)carbonyl]amino}-7-ethoxy-7-oxoheptanoyl]-L-glutaminyl-L-prolyl-L-leucine | Formula: | C33 H49 N5 O10 | Definition date: | 2012-12-12 | Last modified: | 2013-06-03 |
|
| PRD_000321 | Name: | N-{(2S)-2-[(L-asparaginyl-L-leucyl)amino]-1,1-dihydroxy-4-methylpentyl}-L-threonyl-L-glutaminyl-L-isoleucine | Formula: | C31 H58 N8 O11 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_001096 | Name: | TMC-95A | Formula: | C33 H38 N6 O10 | Definition date: | 2012-12-12 | Last modified: | 2020-07-29 |
|
| PRD_000322 | Name: | amino({(4S)-4-[({(3S)-3-[(benzylsulfonyl)amino]-2-oxopiperidin-1-yl}acetyl)amino]-5-oxopentyl}amino)methaniminium | Formula: | C20 H31 N6 O5 S | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000323 | Name: | (2S)-2-[(2-amino-1,3-thiazol-4-yl)methyl]-N~1~-[(1S,2R,3R)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-N~4~-[2-(d
imethylamino)-2-oxoethyl]-N~4~-[(1S)-1-phenylethyl]butanediamide | Formula: | C34 H53 N5 O5 S | Definition date: | 2012-12-12 | Last modified: | 2022-03-02 |
|
| PRD_001098 | Name: | TMC-95A mimic ligand 2b | Formula: | C42 H47 N5 O8 | Definition date: | 2012-12-12 | Last modified: | 2013-06-03 |
|
| PRD_000324 | Name: | 2-{(3S)-3-[(benzylsulfonyl)amino]-2-oxopiperidin-1-yl}-N-{(2S)-1-[(3R)-1-carbamimidoylpiperidin-3-yl]-3-oxopropan-2-yl}acetamide | Formula: | C23 H34 N6 O5 S | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000325 | Name: | Nalpha-[(4-methylpiperazin-1-yl)carbonyl]-N-[(3S)-1-phenyl-5-(phenylsulfonyl)pentan-3-yl]-L-phenylalaninamide | Formula: | C32 H40 N4 O4 S | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_001100 | Name: | N-(benzylsulfonyl)-D-alanyl-N-(4-carbamimidoylbenzyl)-L-prolinamide | Formula: | C23 H29 N5 O4 S | Definition date: | 2012-12-12 | Last modified: | 2012-12-12 |
|
| PRD_001101 | Name: | N-(benzylsulfonyl)-D-valyl-N-(4-carbamimidoylbenzyl)-L-prolinamide | Formula: | C25 H33 N5 O4 S | Definition date: | 2012-12-12 | Last modified: | 2012-12-12 |
|
| PRD_000326 | Name: | cyclo(L-alpha-aspartyl-L-tryptophyl-L-alpha-glutamyl-L-phenylalanyl-D-prolyl-L-prolyl-L-phenylalanyl-L-alpha-glutamyl-6-chloro-L-tryptophyl-L-leucyl) | Formula: | C70 H81 Cl N12 O16 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000328 | Name: | N-[(benzyloxy)carbonyl]-L-alanyl-N-{(1S)-1-[(R)-[(1R)-1-benzyl-2-methoxy-2-oxoethoxy](hydroxy)phosphoryl]-3-methylbutyl
}-L-alaninamide | Formula: | C29 H40 N3 O9 P | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000329 | Name: | N~2~-[(benzyloxy)carbonyl]-N-[(1R,2S)-1-(dihydroxyboranyl)-2-methylbutyl]-L-alaninamide | Formula: | C16 H25 B N2 O5 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_001103 | Name: | TMC-95A mimic ligand 2a | Formula: | C42 H47 N5 O7 | Definition date: | 2012-12-12 | Last modified: | 2013-06-03 |
|
| PRD_000330 | Name: | (5S,8R,11S)-8-(2-carboxyethyl)-5-(carboxymethyl)-14-(4-ethoxy-4-oxobutanoyl)-11-(1-methylethyl)-3,6,9,12-tetraoxo-1-phenyl-2-oxa-4,7,10,13,14-pentaazahexadecan-16-oic acid | Formula: | C30 H41 N5 O14 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
| PRD_000331 | Name: | N-[(benzyloxy)carbonyl]-L-alpha-aspartyl-L-alpha-glutamyl-L-valyl-L-aspartic acid | Formula: | C26 H34 N4 O12 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_001105 | Name: | TMC-95A mimic ligand 2c | Formula: | C42 H47 N5 O8 | Definition date: | 2012-12-12 | Last modified: | 2013-06-03 |
|